Feature|Videos|May 30, 2025

From Discovery to Delivery: How Piramal Pharma Limited is Strengthening its Drug Development Capabilities

Peter DeYoung, CEO at Piramal Pharma Limited, explains how Piramal is meeting the growing demand for integrated biologics manufacturing by expanding capabilities and expertise.

One of the most recent changes at Piramal Pharma Limited is the expansion of its U.S. facility, doubling sterile fill-finish capacity and adding commercial-scale lyophilization to meet growing demand for U.S. containment and antibody-drug conjugate (ADC) support. The company has also enhanced its Science Collective by onboarding senior leaders in discovery and small molecule chemistry, enabling deeper technical collaboration with clients across modalities such as peptides, small molecules, and ADCs. Lastly, their global sustainability and digitalization initiatives have shifted to support future AI-driven manufacturing and quality solutions.

Learn More About:

  • How Piramal as a leading global CDMO is expanding to meet market demands and patient needs
  • Their seamless integration of facilities and expert team of industry leaders, enabling them to provide comprehensive services across the entire drug life cycle
  • The role of patient centricity at the heart of their operations, with a goal to reduce the burden of disease for patients worldwide

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.